These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28126200)

  • 21. Diagnosis and management of early asthma in preschool-aged children.
    Bacharier LB; Guilbert TW
    J Allergy Clin Immunol; 2012 Aug; 130(2):287-96; quiz 297-8. PubMed ID: 22664162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pratical aspects of anti-Ige therapy in severe allergic asthma].
    Taramarcaz P; Hauser C; Rochat T
    Rev Med Suisse; 2007 Apr; 3(108):1050-2, 1054-5. PubMed ID: 17552257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The spectrum of asthma: an introduction.
    Calhoun WJ
    Adv Exp Med Biol; 2014; 795():1-4. PubMed ID: 24851269
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduction of the total immunoglobulin E level by omalizumab in children and adolescents.
    Steiss JO; Rudloff S; Lindemann H; Zimmer KP
    J Asthma; 2010 Sep; 47(7):832-3. PubMed ID: 20653498
    [No Abstract]   [Full Text] [Related]  

  • 25. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
    Fajt ML; Wenzel SE
    J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgE mediated sensitisation to aeroallergens in an asthmatic cohort: relationship with inflammatory phenotypes and disease severity.
    Manise M; Bakayoko B; Schleich F; Corhay JL; Louis R
    Int J Clin Pract; 2016 Jul; 70(7):596-605. PubMed ID: 27352803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgE-mediated asthma: New revelations and future insights.
    Djukanovic R; Hanania N; Busse W; Price D
    Respir Med; 2016 Mar; 112():128-9. PubMed ID: 26577335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of phenotypes of elderly patients with asthma.
    Sano H; Iwanaga T; Nishiyama O; Sano A; Higashimoto Y; Tomita K; Tohda Y
    Allergol Int; 2016 Apr; 65(2):204-209. PubMed ID: 26786397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biologicals in the Treatment of Bronchial Asthma].
    Haasler I; Taube C
    Pneumologie; 2017 Oct; 71(10):684-698. PubMed ID: 29017221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing is everything: Targeting IgE to reduce asthma exacerbation risk.
    O'Byrne PM; Tworek D
    J Allergy Clin Immunol; 2015 Dec; 136(6):1486-1487. PubMed ID: 26654197
    [No Abstract]   [Full Text] [Related]  

  • 32. Underestimating asthma severity--variability of classifications and outcomes.
    O'Connor RD
    Manag Care; 2004 Jul; 13(7 Suppl Reversing Asthma):3-8; discussion 17-9. PubMed ID: 18567140
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhaled allergen challenge in assessment of biologics for asthma.
    Robinson DS
    Clin Exp Allergy; 2014 Jan; 44(1):2-5. PubMed ID: 24355015
    [No Abstract]   [Full Text] [Related]  

  • 34. [Omralizumab (Xolair) in severe persistent allergic asthma].
    Schleich F; Manise M; Louis R
    Rev Med Liege; 2009; 64(5-6):313-7. PubMed ID: 19642466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort.
    Haselkorn T; Mink D; Kianifard F; Ortiz B; Paknis B; Lecocq J; Chipps BE; Bleecker ER
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):593-595. PubMed ID: 34391902
    [No Abstract]   [Full Text] [Related]  

  • 36. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
    Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
    Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibitory effects of kaempferol-3-O-rhamnoside on ovalbumin-induced lung inflammation in a mouse model of allergic asthma.
    Chung MJ; Pandey RP; Choi JW; Sohng JK; Choi DJ; Park YI
    Int Immunopharmacol; 2015 Apr; 25(2):302-10. PubMed ID: 25698556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program.
    DeMeo DL; Lange C; Silverman EK; Senter JM; Drazen JM; Barth MJ; Laird N; Weiss ST
    Genet Epidemiol; 2002 Nov; 23(4):335-48. PubMed ID: 12432502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ; Singh H; Diaz J; Peters JI
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Badly controlled severe persistent asthma: an additional new treatment].
    Nomémie L; Verpilleux MP; Ballouard K
    Soins; 2006 Dec; (711):19-21. PubMed ID: 17274408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.